Compare KIO & ABSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KIO | ABSI |
|---|---|---|
| Founded | 2011 | 2011 |
| Country | United States | United States |
| Employees | 2400 | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 478.7M | 577.4M |
| IPO Year | N/A | 2021 |
| Metric | KIO | ABSI |
|---|---|---|
| Price | $11.63 | $3.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $7.98 |
| AVG Volume (30 Days) | 136.5K | ★ 3.9M |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 10.82% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,815,000.00 |
| Revenue This Year | N/A | $10.72 |
| Revenue Next Year | N/A | $437.79 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.52 | $2.01 |
| 52 Week High | $13.59 | $6.33 |
| Indicator | KIO | ABSI |
|---|---|---|
| Relative Strength Index (RSI) | 46.75 | 49.46 |
| Support Level | $11.55 | $3.37 |
| Resistance Level | $11.69 | $3.79 |
| Average True Range (ATR) | 0.08 | 0.23 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 52.33 | 14.79 |
KKR Income Opportunities Fund operates as a closed-end registered management investment company. The Fund's main objective is to generate a high level of current income, with a secondary objective of capital appreciation. The company invests in a portfolio of loans and fixed-income instruments of U.S. and non-U.S. issuers. The company will invest at least 80% of its Managed Assets in loans and fixed-income instruments or other instruments, including derivative instruments, with similar economic characteristics under normal market conditions.
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.